About Kinesin-like protein KIFC3
Kinesin-like protein KIFC3 (KIFC3) is a protein
from Homo sapiens identified by UniProt accession
Q9BVG8, 833 residues long.
MolForge cross-references it against 0 known binders and
67 disease associations.
Target properties
| Protein name | Kinesin-like protein KIFC3 |
|---|
| UniProt accession | Q9BVG8 |
|---|
| Gene | KIFC3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 833 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BVG8-F1 | alphafold | PREDICTED | 74.20 | — |
Amino-acid sequence (833 residues)
MVPSRRTWNL GATPSLRGLW RVGRAPEPEP GMARPAPAPA SPAARPFPHT GPGRLRTGRG KDTPVCGDED SSARSAARPA LAQCRALSVD WAGPGSPHGL YLTLQVEHLK EKLISQAQEV SRLRSELGGT DLEKHRDLLM VENERLRQEM RRCEAELQEL RTKPAGPCPG CEHSQESAQL RDKLSQLQLE MAESKGMLSE LNLEVQQKTD RLAEVELRLK DCLAEKAQEE ERLSRRLRDS HETIASLRAQ SPPVKYVIKT VEVESSKTKQ ALSESQARNQ HLQEQVAMQR QVLKEMEQQL QSSHQLTARL RAQIAMYESE LERAHGQMLE EMQSLEEDKN RAIEEAFARA QVEMKAVHEN LAGVRTNLLT LQPALRTLTN DYNGLKRQVR GFPLLLQEAL RSVKAEIGQA IEEVNSNNQE LLRKYRRELQ LRKKCHNELV RLKGNIRVIA RVRPVTKEDG EGPEATNAVT FDADDDSIIH LLHKGKPVSF ELDKVFSPQA SQQDVFQEVQ ALVTSCIDGF NVCIFAYGQT GAGKTYTMEG TAENPGINQR ALQLLFSEVQ EKASDWEYTI TVSAAEIYNE VLRDLLGKEP QEKLEIRLCP DGSGQLYVPG LTEFQVQSVD DINKVFEFGH TNRTTEFTNL NEHSSRSHAL LIVTVRGVDC STGLRTTGKL NLVDLAGSER VGKSGAEGSR LREAQHINKS LSALGDVIAA LRSRQGHVPF RNSKLTYLLQ DSLSGDSKTL MVVQVSPVEK NTSETLYSLK FAERVRSVEL GPGLRRAELG SWSSQEHLEW EPACQTPQPS ARAHSAPSSG TSSRPGSIRR KLQPSGKSRP LPV
Explore Kinesin-like protein KIFC3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets